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Abstract
Background: The transporter associated with antigen processing (TAP) supplies cytosolic peptides into the endoplasmic
reticulum for binding to major histocompatibility complex (MHC) class I molecules. Its specificity therefore influences the
repertoire of peptides presented by MHC molecules. Compared to human TAP, murine TAP’s binding specificity has not
been characterized as well, even though murine systems are widely used for basic studies of antigen processing and
presentation.
Methodology/Principal Findings: We performed a detailed experimental analysis of murine TAP binding specificity by
measuring the binding affinities of 323 peptides. Based on this experimental data, a computational model of murine TAP
specificity was constructed. The model was compared to previously generated data on human and murine TAP specificities.
In addition, the murine TAP specificities for known epitopes and random peptides were predicted and compared to assess
the impact of murine TAP selectivity on epitope selection.
Conclusions/Significance: Comparisons to a previously constructed model of human TAP specificity confirms the well-
established differences for peptide substrates with positively charged C-termini. In addition these comparisons show that
several residues at the N-terminus of peptides which strongly influence binding to human TAP showed little effect on
binding to murine TAP, and that the overall influence of the aminoterminal residues on peptide affinity for murine TAP is
much lower than for the human transporter. Murine TAP also partly prefers different hydrophobic amino acids than human
TAP in the carboxyterminal position. These species-dependent differences in specificity determined in vitro are shown to
correlate with the epitope repertoire recognized in vivo. The quantitative model of binding specificity of murine TAP
developed herein should be useful for interpreting epitope mapping and immunogenicity data obtained in humanized
mouse models.
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Introduction
CD8
+ T lymphocytes monitor cells for non-self protein
expression by scanning their surface for MHC class I molecules
presenting peptides derived from proteins expressed inside the cells
[1]. The recognition of peptide epitopes by T cells mediates the
clearance of viral infections [2–4], controls the growth of
intracellular bacteria [5–8], and has a role in immunity against
some types of cancer [9]. Defects in self tolerance can lead to
CD8
+ immune responses that contribute to autoimmune pathol-
ogies [10]. The importance of CD8
+ immune responses for human
health has motivated many in vivo studies aiming to identify the
peptide targets of CD8
+ responses. As studies with human patients
are often not ethically feasible and samples can be hard to obtain,
many epitope discovery studies have been conducted in human-
ized mice [11–13]. It is therefore important to understand
differences between murine and human antigen processing
machinery that may affect the identity and immunodominance
of HLA class I-restricted peptide epitopes.
The majority of peptides recognized by CD8
+ T cells are
generated through the endogenous MHC-I antigen processing and
presentation pathway. Initially proteins in the cytosol are cleaved
into peptide fragments by proteasomes, possibly in concert with
TPPII [14,15], and by other proteases. The produced peptides are
subject to rapid degradation by cytosolic aminopeptidases, and
only approximately 1% of the peptides [16,17] escape degradation
through transport into the ER by the TAP transporters that prefer
peptides with a length of 8 to 16 residues [18–20]. Inside the ER,
peptides are subject to further N-terminal trimming by ERAP1,
which efficiently cleaves substrates between 8 and 16 residues in
length [21]. In humans, an additional ER aminopeptidase,
ERAP2, with a preference for basic residues, complements
ERAP1 [22]. Finally, peptides with suitable length and sequence
are able to bind empty MHC class I molecules with the help of
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The peptide:MHC complex is then transported to the cell surface
through the Golgi apparatus. Sequence specificities at each step in
this antigen processing pathway influence what peptides are
eventually presented to T cells.
The focus of the present study is the murine TAP transporter, a
heterodimeric complex consisting of the TAP1 and TAP2
proteins, both of which are members of the ATP binding cassette
(ABC) transporter family [23]. Peptide transport by TAP is a
sequential process initiated by peptide binding to a site probably
located at the interface between the cytosol and the transmem-
brane channel of TAP, followed by ATP dependent transport of
the peptide into the ER [24]. Two assays measuring peptide
affinity for TAP are available. One of these measures the ATP-
and temperature-dependent accumulation of glycosylated trans-
ported peptides in the ER [25]. This assay has the advantage of
measuring the complete peptide transport process, but may also be
affected by the rate of peptide degradation in the cytosol either
before transport into the ER, or after retrograde transport out of
the ER [18,26,27]. While cytosolic peptide degradation is
generally extremely rapid, some peptides, for example those with
multiple basic residues in the aminoterminal positions, have been
found to be more resistant to degradation [15,28]. A second assay
measures only the initial peptide binding step at low temperature,
rendering interference by peptidases less likely [20]. While it was
theoretically conceivable that some peptides bind TAP but are not
transported, which would have rendered the latter assay
unreliable, it has been found that addition of very long side
chains is required to produce peptides that bind TAP without
being transported [29]. Moreover, it has been directly demon-
strated that peptide binding affinity reflects peptide transport
affinity [30,31]. Further strong evidence for the biological
relevance of the results of TAP binding assays was provided in a
study showing that TAP binding affinity paralleled closely the
efficiency of epitope presentation by cell surface class I molecules
[17]. The fact that an algorithm that is based on the TAP affinity
of a large number of peptides measured using the binding assay,
ameliorates prediction of naturally processed CTL epitopes
represents an additional corroboration of the binding assay [32]
The first in vitro studies characterizing the sequence specificity of
TAP peptide transport focused mainly on C-terminal peptide
residues. Murine and rat cim
b TAP molecules prefer peptides with
hydrophobic C-termini [19,33,34], while human TAP molecules
transport efficiently peptides with hydrophobic and basic C-
terminal residues [34]. Additional studies of the influence of the
aminoterminal and internal peptide sequence, carried out using
the peptide transport assay, concluded that these positions have
little effect on TAP affinity, with the exception of Pro residues in
several positions which decreased transport efficiency [34–36].
However, detailed studies of human TAP specificity using the
peptide-binding assay elucidated a significant influence of the
three N-terminal peptide residues [31,32,37,38]. The same
preferences are found in peptides of different lengths for the first
three N-terminal and the C-terminal positions. This makes it likely
that peptide binding to TAP involves two contact sites at the free
peptide ends, with each having a defined binding preference, while
the connecting residues can form loops of variable lengths [37].
This model would also explain why there is a minimal peptide
length required for efficient transport [18–20].
In summary, while past studies with model substrates have
demonstrated differences between murine and human TAP
specificity, subsequent large-scale studies that allow for the
development of general quantitative prediction models have focused
on human TAP alone. In this study, we have therefore characterized
the binding specificity of murine TAP with a large panel of peptides,
allowingforadetailedcomparisonbetweenthetransportpreferences
in the two species. We have further utilized this data to build a
predictive model of TAP transport for peptides of any length, which
can be applied to identify likely epitopes or their precursors.
Results
Establishing the murine TAP binding assay
We previously established an assay measuring competition for
binding to human TAP complexes, over-expressed in insect cells,
between a radio-labeled reporter peptide and unlabeled test peptides
[20]. In this study, standard procedures were utilized to produce
recombinant baculoviruses driving expression of the murine TAP1
and TAP2 transporter subunits, as confirmed by immunoblot
analysis (not shown). Formation of TAP1/TAP2 complexes able to
bind peptides was measured using peptide R9L (RRYNASTEL) as a
standard reporter [20], labeled with
125I. Figure 1 shows a
Scatchard plot analysis of
125I-R9L binding to microsomes from Sf9
cells co-infected with mouse TAP1 and TAP2 viruses. This
experiment indicates 8610
6 binding-competent TAP complexes
perSf9 cell, anda KD of 400 nMfor thereporter peptide.Previously
established values for human TAP complexes expressed in Sf9 cells
are 1610
6 and 390 nM, respectively [20]. Thus, mouse TAP
complexes are expressed with very high efficiency in our insect cell
system,and bind thestandard reporterpeptide with thesameaffinity
as human TAP complexes.
Using the same insect cell system for TAP expression, a novel
assay was established which is based on detecting fluorescence
polarization rather than the activity of a radioactive tracer. A
reporter peptide was synthesized in which position 6 (Ser) of peptide
R9L was substituted by a Cys residue coupled to a fluorescein group
(R9L-FITC). As expected [20], this peptide did not bind to
microsomes containing either murine TAP1 or TAP2 protein alone
(data not shown). To establish a fluorescence polarization assay, we
determined the concentrations of reporter peptide and microsomes
yielding the highest specific binding signal (mP reading). Optimal
results were obtained with a peptide concentration of 20 nM and a
microsome volume of 10 ml( Figure 1).
Table 1 shows an example of assay results, with five peptides at
each end of the range of affinities measured in the assay. Measured
relative affinities range over more than five logs. As expected from
previous characterizations of murine TAP specificity, many
peptides with very low affinities have a C-terminal Lys residue,
while high affinity peptides have a hydrophobic C-terminus.
Thus, the combination of very high-level expression of mouse
TAP complexes in Sf9 microsomes, and high affinity binding of
the reporter peptide R9L-FITC to these complexes, allowed us to
establish a highly efficient novel binding assay for characterizing
the specificity of mouse TAP transporters. Of note, this assay not
only avoids the use of radioactive tracers but also is significantly
faster than our previous assay since microsome washing for
removal of free peptide ligand is not required.
The fluorescence polarization assay was validated by comparing
data obtained using insect cell-expressed human TAP complexes
and reporter peptide R9L-FITC (which binds to human TAP with
identical affinity), with data previously generated in the radioli-
gand binding assay. These experiments showed that peptide
affinities determined in the two assays were within the margin of
experimental error of each other (data not shown).
Selecting and testing peptides for binding to murine TAP
We selected and tested peptides for binding to murine TAP
binding in a two-stage process. In the first stage, we selected a set
Murine TAP Specificity
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murine T cell epitopes and other peptides chosen from natural
protein sequences. These peptides were chosen so to ensure that all
amino acids were represented at all nine positions in at least two
peptides of the dataset.
In the second stage, we selected a set of peptides using a ‘‘query
by committee’’ (QBC) approach [39,40], which should minimize
any holes in knowledge left after the first set. Briefly, five prediction
models were generated, each based on randomly drawn 80% of
the current binding data. These five models were used to predict
the binding affinity of 50,000 peptides of length nine. Thirty-three
peptides were chosen that had an at least 25-fold difference
between the highest and lowest of the five predicted IC50 values.
Such peptides represent likely holes in knowledge, because no
robust prediction for their IC50 value was determined from the
initial set of peptides. In total, we determined the binding affinities
of 231 peptides of length 9, which are listed in Table S1.
Establishing a predictive model for 9-mer binding to
murine TAP
We utilized the set of measured binding affinities to generate a
prediction model of murine TAP specificity, and evaluated its
accuracy. The SMM-BP algorithm was used to determine a
scoring matrix of murine TAP specificity. Briefly, the algorithm
determines the matrix by minimizing the difference between
measured and predicted affinities, while preferring matrices that
assign similar scores to amino acids known to have similar binding
characteristics (see Material & Methods). To evaluate the quality
of the binding prediction, we used 5-fold cross validation: the
peptides were randomly partitioned into 5 mutually exclusive
subsets. For the validation, one of the 5 subsets was used as the test
set and the other 4 subsets were combined to form a training set. A
prediction was generated using only peptides from the training set,
and used to predict the affinity of all peptides in the blind set.
Repeating this process 5 times gives one affinity prediction for
each peptide in the original set, which can be compared to its
known measured affinity. Figure 2 depicts the results of the cross Figure 1. Establishing the murine TAP binding assay. Panel A
depicts a Scatchard plot analysis of
125I-labeled peptide binding to
murine TAP1/TAP2 complexes. The lower panels depict dilution series
determining the optimal concentrations for (B) the fluorescent reporter
peptide and (C) the volume of microsomes expressing murine TAP.
Maximal specific binding, as measured by the polarization reading (y-
axis), is achieved at 20 nM reporter peptide and 10 ml of microsomes.
doi:10.1371/journal.pone.0002402.g001
Figure 2. Assessing prediction quality through cross-valida-
tion. Each point in the scatterplot represents one peptide. For each
peptide, the measured affinity (x-axis) is plotted against the predicted
affinity (y-axis). The predicted values were obtained in a blinded 5-fold
cross-validation.
doi:10.1371/journal.pone.0002402.g002
Table 1. Highest and lowest measured murine TAP affinities
Sequence relative IC50
AAFEFINSL 0.11
RDAEFVMCL 0.15
GTHVLLPFY 0.16
NLYISDYKM 0.23
AIITPVVFY 0.25
LLAVCGCIE .5000
NIVYKKNNR .5500
KTGGPIYKR .5800
NMEANDPEK .6000
NQSSHKGVG .7000
doi:10.1371/journal.pone.0002402.t001
Murine TAP Specificity
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ed affinities was highly significant (Pearson r
2=0.52, p,0.0001).
85% of the peptides had a measured affinity within 10-fold range
of the predicted IC50 value. In conclusion, we have established a
matrix model of 9-mer peptide binding to murine TAP that
correlates well with measured affinities in a blinded evaluation.
Next, we examined the influence of specific peptide residues on
binding to murine TAP determined in our matrix model. Figure 3a
shows the prediction matrix for murine TAP that assigns a score to
each residue in a 9-mer peptide. The scores approximate the
contribution to binding free energy of the corresponding peptide
residue. Residues at peptide positions 1, 2, 3 and 9 (the C-
terminus) have the greatest influence on binding to murine TAP,
similar to previous observations for human TAP [31]. At the C-
terminus, hydrophobic residues are the most preferred for murine
TAP, in agreement with previous reports [19,34]. At positions 1,2
and 3, the most notable impact on binding is the strong negative
influence of proline which had also been reported before [34,36].
The remaining matrix entries with significant scores (R2, D3, F3,
Y3, D4 and Y8) were not singled out as influential residues in the
one study looking at the impact of those positions [36]. This is
likely due to their lower impact compared to the C-terminal and
Proline residues, as well as the fact that several residues including
D and R were missing from the panel tested in [36]. Overall, the
specificity matrix calculated by us for murine TAP is in good
qualitative agreement with previously published experimental data
generated with model substrates.
In order to identify residue positions contributing to the difference
between murine and human TAP specificity, we compared the
murine matrix scores with those of a previously determined human
TAPspecificitymatrix [32].Figure3 depicts thetwo matricessideby
side, and identifies residues with absolute score differences above
0.55 with a bold border. The most drastic difference between matrix
scores was observed for Lysine (K) and Arginine (R) at the C-
terminus. This corresponds to the previously described finding that
only human but not murine TAP complexes can bind peptides with
positively charged C-termini [34,41]. Methionine (M) and Trypto-
phane (W) are strongly preferred residues for binding at the C-
terminus of murine TAP, while they have little or no effect for
human TAP. Moreover, compared to the human TAP matrix, the
charged residues D and E are essentially neutral in positions 1 and 2
of murine TAP,whereas they clearly inhibitbinding to human TAP.
Finally, Proline (P) at position 3 disrupts binding to murine TAP
while beingessentialneutral forthe humantransporter.Insummary,
although the relative weight of the aminoterminal positions differs
between human and murine TAP (see below), binding affinity for
both depends mainly on the three N-terminal and the C-terminal
residues of a peptide. While the two transporters share many
preferences, there are a number of residues with clearly distinct
binding patterns.
Next we examined the overall importance of C-terminal and N-
terminal peptide residues for binding to human and mouse TAP.
Mouse TAP has strong preferences or aversion for 13 of 20 amino
acids at the C-terminus, while human has only 7. Conversely,
human TAP shows preferences or aversion for 16 amino acids in
positions 1 to 3 (6 in P1, 4 in P2, 6 in P3), while mouse TAP
displays only 7 (1 in P1, 2 in P2, 4 in P3). At the C-terminus, this
difference is statistically significant when comparing the absolute
coefficient values (p=0.030, Mann-Whitney Test). For the three
N-terminal residues, the p value is 0.062, just slightly above the
customary cutoff of p=0.05.
To quantify the relative impact of N-terminal residues and the
C-terminus with a single number, we calculated the ratio of
standard deviations for the scores for human and mouse TAP at
the corresponding positions. For human TAP, the standard
deviation of the C terminal scores is 0.59 and 0.41 at the N-
terminus, which gives a ratio of 1.4. In contrast, for murine TAP
the standard deviation at the C-terminus is 0.82 and 0.31 at the N-
terminus, corresponding to a ratio of 2.6 which is nearly twice as
high. Overall this shows that murine TAP selects its ligands much
more on the basis of the C terminus than its human counterpart.
Predicting peptide binding for varying lengths
As TAP is known to transport precursor peptides longer than
nine residues into the ER, we examined if we could predict their
affinity using an approach we had previously developed for human
Figure 3. Binding specificity of murine and human TAP. The matrices were generated from peptide binding data to murine (left) or human
(right) TAP molecules. Each column in the matrix corresponds to a position in a peptide of length 9, and each row to a certain residue. Negative
values (marked in green for x,20.5) correspond to residues with higher affinities, while positive values (marked in red for x.0.5) correspond to
lower affinities. Matrix positions that differ by more than 0.55 between the two species are boxed.
doi:10.1371/journal.pone.0002402.g003
Murine TAP Specificity
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their three N-terminal residues plus their one C-terminal residue,
and assigning them a binding score based on matrix columns 1, 2,
3 and 9 of the matrix for 9-mer peptides. To evaluate this
approach, we first tested a set of 92 peptides with length 8, 10 and
11 for binding to murine TAP (Table S1). Figure 4 shows
scatterplots of the predicted versus measured affinities for each of
these peptides, using either the human or the murine matrices as
predictors. The correlation between prediction and measurement
is highly significant for the murine matrix predictions (r
2=0.58,
p,0.01), even slightly above the correlation determined above in
cross-validation using 9-mers alone. The results for individual
peptide sets are similar, with 8-mers, 10-mers and 11-mers having
correlations coefficients r
2 of 0.53, 0.67 and 0.64, respectively. In
addition, we have compared how the human TAP matrix would
have performed on this peptide set. As shown in Figure 4,
predictions based on human TAP data would have correlated very
poorly with the experimental results (r
2=0.21). Overall, this
confirms that our approach can be used to predict peptide binding
for multiple lengths to murine TAP, and that murine TAP has a
distinct binding pattern from that of human TAP.
Prediction of T-cell recognition
Next, we tested if our murine TAP transport predictions could
identify which peptides contained in a pathogen are recognized as T
cell epitopes. As a test set, we used epitopes identified in H-2
b or H-
2
d mice following viral infections with LCM or Vaccinia virus
(described in [42,43] and Oseroff, manuscript submitted). As T cell
priming during infection requires processing and presentation of
peptides in infected target cells, peptides that are recognized post
infection are presumed to be at least permissible for TAP transport.
A totalof139 epitopes restricted byH-2 D
b,K
b,D
d,K
d and L
d were
included in this set, including 34 8-mers, 96 9-mers, 6 10-mers and 3
11-mers. For each virus, we predicted the TAP affinity of all 8, 9, 10
and 11mer peptides that can be derived from their viral source
proteins. In Figure 5, these predicted affinities are compared for
peptides recognized as T cell epitopes and non-epitopes. As
expected, T cell epitopes showed markedly higher TAP affinities
than non-epitopes. For example, 43% of all epitopes have a
predicted IC50 ,10 nM, while only 14% of non-epitope peptides
have a similar high affinity. Overall, this confirmsthat a peptide with
high predicted murine TAP affinity has an increased probability of
being recognized by T cells following viral infections in mice.
Figure 4. Prediction quality for peptides of varying lengths. Each scatterplot represents predicted vs. measured affinities for the set of 8, 10
and 11-mer peptides tested for binding to murine TAP. The predictions on the left plot were made with the murine TAP prediction matrix, the one in
the right plot using the previously established human TAP matrix.
doi:10.1371/journal.pone.0002402.g004
Figure 5. Utilizing TAP transport predictions to identify T cell epitopes. Peptides from LCMV and VACV were classified into either epitopes
or non-epitopes depending on their recognition by T cells in mice post infection (see Methods). In the left panel, murine TAP affinity predictions
were made for all peptides. At varying cutoffs, the cumulative percentage of epitope and non-epitope peptides that have an affinity of at least the
cutoff is given. In the right panel, an ROC plot is used to directly compare the murine and human predictions. The curve made with murine TAP
predictions is consistently better at separating murine epitopes from non-epitopes than the human one.
doi:10.1371/journal.pone.0002402.g005
Murine TAP Specificity
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murine TAP specificity influences the epitope repertoire recognized
by human and murine T cells. If this is indeed the case, the
correlation between predicted murine TAP affinity and T cell
recognition in mice should be higher than for predicted human TAP
affinity. We utilized ROC curves to directly compare the ability of
both predictions to identify murine T cell epitopes (Figure 5), which
clearly demonstrated superior performance for the murine TAP
prediction. This confirms that the murine TAP predictions are
superior to human ones at identifying epitopes recognized in mice.
For human TAP, we had previously shown that taking the
transport of epitope precursors into account can greatly improve
the prediction quality [32]. We applied the same approach to
murine TAP by averaging the score of precursor peptides up to a
maximal extension Nmax, and assigning a weighting factor a.W e
tested the performance of these predictions on the same dataset
used in Figure 5 for varying values of Nmax and a. The prediction
performance was only marginally improved, below the threshold
for statistical significance for all parameter combinations. Thus,
the previously established approach to improve epitope predictions
for human TAP by including the transport of precursors was not
successful when applied to murine TAP and the prediction of viral
epitopes. This demonstrates that the predominant influence of C-
terminal peptide residues on murine TAP affinity reduces the
impact of different N-terminally prolonged precursors being
transported on epitope recognition in mice.
Discussion
We here presented a large-scale analysis of murine TAP
specificity obtained using TAP binding assays. The quantitative
binding affinity of 231 9-mer peptides was determined, and used to
computationally derive murine TAP specific scoring matrices. The
resulting specificity pattern is in good agreement with previous
publications that used peptide substitution libraries to directly
compare different residues in one position on the affinity or
transport rates of murine TAP[19,34,36]. In addition, the present
study provides the first quantitative specificity data for over
seventy residue/position combinations not covered by published
substation library data. This complete coverage ensures that no
residue/position combination that strongly influences binding has
been overlooked, which is necessary to quantitatively predict
murine TAP binding specificity for any peptide sequence.
We took advantage of being able to compare human and murine
TAP specificity matrices, and found that several residues at the N-
terminus of peptides that strongly influence binding to human TAP
showed little effect on binding to murine TAP. This includes a
complete lack of any residue with a strong positive effect on binding
inposition 1. In contrast,for peptide C-termini,murineTAP ismore
specific in its binding preference than human TAP. Taken together,
we showed that murine TAP is more skewed than human TAP
towards binding peptides based on their C-terminus alone. While
not reported assignificant intheoriginal publications, examining the
figures in references [34,36] supports such a conclusion.
The differences discovered between human and murine TAP
binding specificity were shown to correlate with differences in the
ability to predict epitope recognition in murine hosts. This
demonstrates that our in vitro studies correlate with antigen
processing events in vivo. It also reinforces that studies of epitope
repertoire in mice and human need to take differences between
their TAP transporters into account.
As TAP is known to transport epitope precursors up to a length
of about 16 residues, it is important to characterize its substrate
specificity for varying lengths. We were able to successfully predict
the affinity of peptides between 8 and 11 residues in length by
modeling their binding interaction at the C terminus and the three
N terminal residues. In this model of binding, the connecting
residues 4 to C-1 of longer peptides are assumed to make only
weak interactions with the TAP molecules. This model was
previously applied to human TAP, and is shown for the first time
to apply to murine TAP as well.
The description of murine TAP specificity provides one crucial
component towards explaining species specific differences in epitope
recognition, which could explain differences in epitope repertoire in
humans and HLA transgenic mice frequently used in epitope
discovery and vaccine development studies. These data likely will
have to be complemented by other studies directed at understanding
the impact of other components of the antigen processing pathway
that are known to differ between the two species. This includes the
lack of ERAP2 in mice, and incompatibilities between human MHC
molecules and the murine peptide loading complex (specifically
tapasin [44]). Also, the difference in mouse and human self, which,
duetotherequirement forself-tolerance,leadstodifferencesinTCR
repertoire, may have to be taken into account. Finally, genomic and
proteomic tools will permit to study host influences on viral protein
expression, or host specific viral immune evasion mechanisms [45],
which will also affect the epitope repertoire in a species specific
manner.
In conclusion, our detailed analysis of the binding specificity of
the murine transporters allows for a sensitive comparison between
peptide selection by mouse and human TAP, and demonstrates
that epitopes recognized by murine CTLs are selected for
increased TAP affinity. This work provides a key step towards
the complete and differential description of human and murine
antigen processing events.
Materials and Methods
Preparation of insect cell microsomes over-expressing
murine TAP complexes
Microsomes were prepared precisely as described previously for
microsomes expressing human TAP. Briefly, full-length cDNAs
encoding the murine TAP transporters were amplified from
plasmids pFM370.1 and pFM372.3 (kindly provided by Frank
Momburg), sequenced, and inserted as XbaI/NotI or BamhI/
XbaI fragments, respectively, into the baculovirus transfer plasmid
pVL1393, and recombinant viruses were produced by co-
transfection of BaculoGold
TM (Pharmingen) linearized baculovirus
DNA together with the plasmids into Sf9 cells, followed by plaque
assays and isolation of clones containing TAP DNA. For
production of microsomes, 175 cm
2 cell culture flasks each
containing 5–8610
6 Sf9 cells were infected at a multiplicity of
infection of 3 with high titer viral supernatant. Three days later,
cells were harvested, broken up in a Douncer, and fractionated
using a sucrose step gradient, as described [20]. One flask of
infected cells yielded on average 1 ml of microsome solution.
Binding Assay
The Scatchard plot shown in Fig. 1 was carried out with
125I-
labeled reporter peptide RRYNASTEL, using exactly the same
conditions as in the Scatchard plot analysis shown in [20]. The
fluorescence polarization assay was carried out entirely at 4uC
according to the following protocol. Peptides were obtained at
,80% purity (Pepscan or Sigma-Genosys); peptide purity was
controlled by HPLC, and identity verified by mass spectrometry.
Peptide stocks were prepared at 10 mM in pure DMSO (50%
DMSO in H2O for peptides with cysteines). Serial dilutions of test
peptides were prepared in assay buffer (PBS with 1 mM
Murine TAP Specificity
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excesses relative to reporter peptide between 0.16 and 10006
could be tested. Dilutions of test peptides and reporter peptide
(final concentration 20 nM) were added to black flat bottom 96-
well plates (FluoroNunc
TM, Nunc) in a total volume of 150 ml.
Then 10 ml of microsomes, diluted to 50 ml in assay, buffer, was
added, and fluorescence polarization immediately read using a
Mithras LB940 microplate reader (Berthold, Thoiry, France).
Unlabeled reporter peptide R9L was included in each assay as
competitor to allow for normalization of data between different
assays. Specific binding was determined as the difference between
the polarization (mP) reading in the absence of competitor to the
reading in the presence of a 1000-fold excess of unlabeled reporter
peptide. The molar excess of the test peptide required for
inhibiting 50% of specific binding of the reporter peptide was
then determined (IC50). Assay results were finally expressed as
ratio, i.e. IC50 of the test peptide divided by the IC50 of the
unlabeled reporter peptide, in order to normalize results among
different assays. Each peptide was tested in at least two
independent assays; if the two results diverged by more than 25
percent, additional assays were performed. The final result
corresponds to the mean of all validated assay results.
Removal of Outliers
A total of five peptides with the sequences ILMIFISSFL,
AFILGIIITV, LMYIFAAL, MIVAWFLLL and WAIINTIYF
were removed from the dataset. For each of these peptides,
relatively weak or no competitive binding to murine TAP could be
determined, even though their sequence strongly suggests them to
be at least reasonable binders. At the same time, these peptides are
very hydrophobic and therefore likely to have problems with
solubility. This would result in them being classified as poor
binders in the assay we employed, which is the basis for their
removal.
SMMBP Method
Peptide binding predictions for TAP and MHC-I molecules
were carried out using the method SMM-BP (manuscript in
preparation), an improved version of SMM [32,46] that includes a
Bayesian Prior (BP). Briefly, this method adds prior knowledge of
amino acid similarities to the matrix determination process, by
including a general amino acid binding covariance matrix. This
covariance matrix was determined directly from a set of 180
randomized peptide libraries of length nine with measured binding
affinities of to 24 MHC-I alleles from human, chimpanzee,
macaque, and mouse (compare [47]). The SMM-BP method
optimizes a scoring matrix such that the squared differences
between measured and predicted binding affinity values are
minimized, which corresponds to maximizing the likelihood of
observing these measurements giving the prediction matrix and
assuming a normal distribution of differences between predicted
and measured values. The prior probability of the scoring matrix is
calculated directly from the amino acid covariance matrix, which
assumes that the scoring matrix follows the same Multivariate
normal distribution. The final matrix is calculated following Bayes’
Theorem by maximizing the product of the probabilities of
likelihood and prior.
T cell epitope dataset
The epitope dataset used were taken from ([42,43] and Oseroff
et al, manuscript submitted). The epitope mapping in the three
studies was performed as follows: C57BL/6 or Balb/c mice were
infected with LCMV Armstrong or VACV WR. Eight to ten days
post infection, mice were sacrificed, and splenocytes were taken.
The cells were tested directly ex vivo in a murine IFN-c ELISPOT
assays for responses against peptide pulsed target cells. The tested
peptides were selected by their predicted ability to bind the H-2
D
b,D
d,K
b,K
d or L
d molecules. Responses were measured in
triplicate, and experiments repeated at least twice. Peptides that
consistently gave responses twice above background and with
SFC/10
6.20 were considered positive. The mice purchased from
The Jackson Laboratory and maintained at the La Jolla Institute
for Allergy and Immunology facility (San Diego, CA) following
National Institutes of Health guidelines and Institutional Animal
Care and Use Committee approved animal protocols.
Supporting Information
Table S1 Experimentally Measured Murine TAP Binding
Affinities for the Peptides.
Found at: doi:10.1371/journal.pone.0002402.s001 (0.04 MB
XLS)
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